Functional Medicine for Diabetes and Dysglycemia

What is dysglycemia?

Dysglycemia is any dysfunction in how the body regulates blood sugar. It covers hypoglycemia, insulin resistance progressing toward diabetes, and autoimmune diabetes. In functional medicine, it is read as a web of vicious cycles across the pancreas, gut microbiome, fat tissue, adrenal glands, liver, kidneys, and brain, rather than one isolated number. The work is to identify the pattern and its severity, then intervene in the right order so the cycle breaks and the patient can produce energy and move toward recovery.

Why Do Patients With Dysglycemia Stay Sick When Standard Labs Look Normal?

Fasting glucose sits in range, the patient feels terrible, and blood sugar gets ruled out. The overlooked problem is that standard panels name diabetes only once it has arrived, while the dysglycemia that drives the symptoms has been building for years. This course teaches a different question and a different order of operations, so the pattern becomes visible and treatable long before a diagnosis would land.

Why do standard labs miss dysglycemia for years?

The earliest sign is a postprandial problem. Glucose and insulin spike after a meal while the fasting number still reads normal. Functional medicine reads markers against optimal ranges and in patterns rather than against a single disease cutoff. Rising triglycerides, a falling HDL, and an LDH under 140 say more together than any one value does alone, which is why the problem is so often missed until it is advanced.

Why is the insulin receptor not the whole story?

The signature model of the course is the physiological web. Blood sugar is not controlled by the pancreas alone. The gut microbiome releases incretins and short-chain fatty acids that tune insulin and glucagon. Fat tissue is an endocrine organ, and enlarged adipocytes pour out inflammatory signals that block the insulin receptor. The adrenal glands raise glucose when it drops, the liver stores and releases it, and the kidneys reabsorb and release about a tenth of the body's glucose. The brain integrates all of it, which is why a traumatic brain injury can cause either diabetes or hypoglycemia. Two master switches, AMPK and the sirtuins, sit over the whole web, and the most useful interventions act through them.

How do you tell hypoglycemia from insulin resistance at the first visit?

Start with body composition and one question: does energy change after you eat? A hypoglycemic patient feels better and sharper after eating, then crashes between meals with shakiness and irritability. An insulin-resistant patient feels tired after meals and reaches for coffee. Most patients carry some of both, so this is a lean, not a label, and lab work settles it.

How severe is it, and why does staging come before treatment?

Prognosis lives on a scale, and the course teaches two. The hyperglycemia scale runs from postprandial surges, to steady insulin resistance, to metabolic syndrome, to diabetes, to diabetes with advanced glycation end products, and finally to nephropathy. The hypoglycemia scale separates a simple loss of resiliency from an underlying metabolic cause, and from true pathological hypoglycemia below 65, which is a red flag for disease. Staging tells you how hard the case will be and where it can still move.

Where do you start so the vicious cycle breaks?

Order is the whole game, and the right first step depends on the pattern. Much of functional medicine says to always start in the gut, but with high circulating insulin that sequence fails. Diet and lifestyle carry the result while nutraceuticals support them, and reaching for supplements first is a failing model. The course details the full sequence for each category so you know what to address, and in what order, for a given patient.

Could it be autoimmune diabetes?

The loudest clue is a lean, healthy patient who eats well, exercises, and still cannot control blood sugar. Latent autoimmune diabetes of adulthood, often called Type 1.5, is far more common than expected, and a large share of adults labeled Type 2 actually carry pancreatic antibodies. The right antibody and C-peptide testing separates these patients out, because they need an autoimmune strategy and a dysglycemia protocol alone will not move them.

For related reading, see Explaining Non-Insurance Functional Labs to Skeptical Patients, Beyond Pharmaceuticals: Integrative Migraine Management, Metabolic Dysfunction as Hidden Driver of Chronic Migraines, and Insulin Resistance Impact on Female Hormone Balance.